Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 223

1.

Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma.

Murakami S, Shahbazian D, Surana R, Zhang W, Chen H, Graham GT, White SM, Weiner LM, Yi C.

Oncogene. 2017 Mar 2;36(9):1232-1244. doi: 10.1038/onc.2016.288. Epub 2016 Aug 22.

2.

Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma.

Zhang W, Nandakumar N, Shi Y, Manzano M, Smith A, Graham G, Gupta S, Vietsch EE, Laughlin SZ, Wadhwa M, Chetram M, Joshi M, Wang F, Kallakury B, Toretsky J, Wellstein A, Yi C.

Sci Signal. 2014 May 6;7(324):ra42. doi: 10.1126/scisignal.2005049.

3.

A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.

Zhao X, Wang X, Fang L, Lan C, Zheng X, Wang Y, Zhang Y, Han X, Liu S, Cheng K, Zhao Y, Shi J, Guo J, Hao J, Ren H, Nie G.

Cancer Lett. 2017 Aug 28;402:61-70. doi: 10.1016/j.canlet.2017.05.015. Epub 2017 May 30.

PMID:
28576749
4.

Role of YAP and TAZ in pancreatic ductal adenocarcinoma and in stellate cells associated with cancer and chronic pancreatitis.

Morvaridi S, Dhall D, Greene MI, Pandol SJ, Wang Q.

Sci Rep. 2015 Nov 16;5:16759. doi: 10.1038/srep16759.

5.

Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development.

Rozengurt E, Eibl G.

World J Gastroenterol. 2019 Apr 21;25(15):1797-1816. doi: 10.3748/wjg.v25.i15.1797. Review.

6.

Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex.

Wei H, Wang F, Wang Y, Li T, Xiu P, Zhong J, Sun X, Li J.

Cancer Sci. 2017 Mar;108(3):478-487. doi: 10.1111/cas.13138.

7.

Yes-associated protein (YAP65) in relation to Smad7 expression in human pancreatic ductal adenocarcinoma.

Guo J, Kleeff J, Zhao Y, Li J, Giese T, Esposito I, Büchler MW, Korc M, Friess H.

Int J Mol Med. 2006 May;17(5):761-7.

PMID:
16596258
8.

SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.

Zhou H, Qin Y, Ji S, Ling J, Fu J, Zhuang Z, Fan X, Song L, Yu X, Chiao PJ.

Oncogene. 2018 Feb 15;37(7):912-923. doi: 10.1038/onc.2017.393. Epub 2017 Oct 23.

9.

Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression.

Kaneda MM, Cappello P, Nguyen AV, Ralainirina N, Hardamon CR, Foubert P, Schmid MC, Sun P, Mose E, Bouvet M, Lowy AM, Valasek MA, Sasik R, Novelli F, Hirsch E, Varner JA.

Cancer Discov. 2016 Aug;6(8):870-85. doi: 10.1158/2159-8290.CD-15-1346. Epub 2016 May 13.

10.

CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer.

Purohit A, Varney M, Rachagani S, Ouellette MM, Batra SK, Singh RK.

Oncotarget. 2016 Feb 9;7(6):7280-96. doi: 10.18632/oncotarget.6906.

11.

KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma.

Ling J, Kang Y, Zhao R, Xia Q, Lee DF, Chang Z, Li J, Peng B, Fleming JB, Wang H, Liu J, Lemischka IR, Hung MC, Chiao PJ.

Cancer Cell. 2012 Jan 17;21(1):105-20. doi: 10.1016/j.ccr.2011.12.006.

12.

Myeloid-derived suppressor cells and their role in pancreatic cancer.

Pergamo M, Miller G.

Cancer Gene Ther. 2017 Mar;24(3):100-105. doi: 10.1038/cgt.2016.65. Epub 2016 Dec 2. Review.

PMID:
27910857
13.

Comparative characterization of stroma cells and ductal epithelium in chronic pancreatitis and pancreatic ductal adenocarcinoma.

Helm O, Mennrich R, Petrick D, Goebel L, Freitag-Wolf S, Röder C, Kalthoff H, Röcken C, Sipos B, Kabelitz D, Schäfer H, Oberg HH, Wesch D, Sebens S.

PLoS One. 2014 May 5;9(5):e94357. doi: 10.1371/journal.pone.0094357. eCollection 2014.

14.

Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.

Barceló C, Etchin J, Mansour MR, Sanda T, Ginesta MM, Sanchez-Arévalo Lobo VJ, Real FX, Capellà G, Estanyol JM, Jaumot M, Look AT, Agell N.

Gastroenterology. 2014 Oct;147(4):882-892.e8. doi: 10.1053/j.gastro.2014.06.041. Epub 2014 Jul 3.

15.

GNASR201C Induces Pancreatic Cystic Neoplasms in Mice That Express Activated KRAS by Inhibiting YAP1 Signaling.

Ideno N, Yamaguchi H, Ghosh B, Gupta S, Okumura T, Steffen DJ, Fisher CG, Wood LD, Singhi AD, Nakamura M, Gutkind JS, Maitra A.

Gastroenterology. 2018 Nov;155(5):1593-1607.e12. doi: 10.1053/j.gastro.2018.08.006. Epub 2018 Aug 22.

PMID:
30142336
16.

Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer.

Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ, Vonderheide RH.

Cancer Cell. 2012 Jun 12;21(6):822-35. doi: 10.1016/j.ccr.2012.04.025.

17.

Yin Yang-1 suppresses pancreatic ductal adenocarcinoma cell proliferation and tumor growth by regulating SOX2OT-SOX2 axis.

Zhang JJ, Zhu Y, Zhang XF, Liu DF, Wang Y, Yang C, Shi GD, Peng YP, Zhang K, Tian L, Miao Y, Jiang KR.

Cancer Lett. 2017 Nov 1;408:144-154. doi: 10.1016/j.canlet.2017.08.032. Epub 2017 Sep 1.

PMID:
28867247
18.

YAP1 and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-regulation of JAK-STAT3 Signaling.

Gruber R, Panayiotou R, Nye E, Spencer-Dene B, Stamp G, Behrens A.

Gastroenterology. 2016 Sep;151(3):526-39. doi: 10.1053/j.gastro.2016.05.006. Epub 2016 May 20.

19.

Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer.

Jiang SH, Wang Y, Yang JY, Li J, Feng MX, Wang YH, Yang XM, He P, Tian GA, Zhang XX, Li Q, Cao XY, Huo YM, Yang MW, Fu XL, Li J, Liu DJ, Dai M, Wen SY, Gu JR, Hong J, Hua R, Zhang ZG, Sun YW.

Oncotarget. 2016 Jan 26;7(4):4226-40. doi: 10.18632/oncotarget.6772.

20.

The GSK3β inhibitor BIS I reverts YAP-dependent EMT signature in PDAC cell lines by decreasing SMADs expression level.

Thongon N, Castiglioni I, Zucal C, Latorre E, D'Agostino V, Bauer I, Pancher M, Ballestrero A, Feldmann G, Nencioni A, Provenzani A.

Oncotarget. 2016 May 3;7(18):26551-66. doi: 10.18632/oncotarget.8437.

Supplemental Content

Support Center